Attendee search 

Based on a fifteen years experience leveraging innovative R & D solutions geared towards chronic disease patients.

Dedicated to selected chronic diseases leading to an efficient management of the healthcare costs, enhanced patient benefits and improved quality of life.

A strong value-added connected health information system and a proven expertise in home healthcare through a series of programs closely connecting patients with health professionals.

An international multidisciplinary team with a proven record in the areas of healthcare, patient care, connected and social computer networks, design and ergonomics and health policy issues.

First transatlantic organization in Applied Telemedicine, offering cost efficient solutions to healthcare payers.

An expertise and proven experience implemented in Europe and complying with stringent privacy and personal information laws for personal health information at the payer, provider and patient level.

• Indigo designs, manufactures and supplies innovative dietary supplements focused on gastrointestinal tract (GIT) pathologies and conditions or deficiencies requiring specific clinical nutrition
• Gynov, Indigo's sister company, applies the same rules of design and manufacturing for gynecological / obstetrics sphere

• Gastroenterology / Hepatology
• Immunology
• Infectious Diseases - Vaccines
• Nutrition and Weight Loss
• Obstetrics/Gynecology (Women's Health)

Besides opportunistic developments, our R&D aims at producing new generation probiotics / synbiotics combining a selection of relevant strains in relation to the progresses on microbiota, a microencapsulation technology promoting the survival and the production of molecules of interest, and a pharmaceutical macro-encapsulation vectorizing active ingredients to the therapeutic target

Indigo addresses medical problems or conditions which currently lack of efficient or well-tolerated solutions. Besides, Indigo provides a clear rational while exploiting the potential of probiotics / synbiotics still faces some uncertainty among healthcare professionals.

Gynov addresses obstetrical issues for which currently available medications are contra-indicated. Thus, Gynov conceives specialized dietary supplements based upon high-quality GRAS ingredients that have demonstrated their efficacy for Gyn/Obst issues

• Irritable bowel disease (IBD)
• Prevention & treatment of diarrheas
• Dialysis for end-stage renal failure
• Fertility & obstetrics

• Robust medico-scientific background
• High manufacturing & product quality (GMP)
• Exclusive promotion towards medical doctors
• High value academic partnerships

TechnoVax is a privately held near-clinical-stage biotechnology company based in Tarrytown, NY specializing in viral vaccine development. Our mission is to create and advance towards the market safe, unique and novel vaccine technologies with no current alternatives that will revolutionize the way vaccines are developed, distributed and administered. 

TechnoVax has developed a next-generation technology-platform based on Virus-Like Particles (VLP) that greatly enhances and facilitates the development and production of a limitless range of vaccines targeting the prevention of respiratory diseases as well as hemorrhagic fevers, immunodeficiency and cancers. The industry strongly believes that VLP based vaccines is the technology of the future! 

Our vaccines pipeline has been rapidly approaching the clinical phases with 3 main candidates: 
- A Universal flu vaccine that will eliminate the need for annual flu vaccination and will protect faster and better against future pandemic strains; 
- An Inhaled Powder flu vaccine that eliminates the need for cold chain storage and distribution and could be self-administered: a greatly needed solution for the developing world; 
- An RSV vaccine to protect against one of the leading causes of infant and elderly hospitalizations and often results in fatalities with the elderly. 

We have received over $5.0 million in non-dilutive funding. We are actively pursuing strategic partnerships and are seeking funding to start human testing.

A clinical research provider that conducts clinical research for pharmaceutical and biotechnological companies as well as government sponsored trials. We also facilitate training programs for clinical research practitioners and site preparation for studies.

We also aim to help clinical research facilities and professionals conduct clinical trials following GCP/ICH. By doing so we believe will be beneficial to pharmaceutical companies as it would allow for clinical trials to run smoother and more efficiently. It will also help subjects get quality service during the clinical studies.

Donec sodales a quam in imperdiet. Aliquam massa libero, malesuada nec interdum sit amet, gravida quis nibh. Praesent facilisis tristique egestas. Curabitur vitae metus vitae libero iaculis suscipit. Nullam non velit metus. Curabitur at euismod felis. Aenean viverra sem sit amet ante bibendum, sit amet vehicula eros dapibus.

Exsight Capital is a venture capital firm specializing in early-stage impact investments in innovative ophthalmic diagnostic and treatment solutions.

Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care teaching facility acclaimed internationally for excellence in clinical care.

U.S. News & World Report ranks The Mount Sinai Hospital among the top hospitals nationwide. Mount Sinai also ranks in several specialties and is top 10 in three of those: Geriatrics (#3), Cardiology and Heart Surgery (#7), and Gastroenterology (#8).

Allovate Therapeutics is a specialty pharmaceutical company dedicated to simplifying allergy treatment. Allovate’s approach to allergy immunotherapy is built around the Allerdent® therapeutic platform. 

Allerdent® is formulated as an easy-to-use, customizable toothpaste that incorporates and stabilizes the immunotherapeutic agents used to treat food and respiratory allergies. It conveniently integrates immunotherapy into an allergy sufferer’s everyday brushing routine. Allerdent® makes tackling allergies as simple as brushing your teeth. 

Clinical investigations led by Allovate Therapeutics are developing this platform for the treatment of food allergies. Allerdent® offers the potential of a long-term solution for the 15 million Americans who have food allergies. 

Allergy immunotherapy is the only disease-modifying allergy treatment, demonstrated to be effective in over 100 years of clinical use. This approach changes how the body responds to allergens over time by exposing the immune system to purified allergen extracts in a controlled way over a period of time. Our approach, oral mucosal immunotherapy (OMIT), is designed to overcome the challenges of existing approaches to immunotherapy. OMIT delivers immunotherapeutic agents to the areas of the oral cavity with the greatest potential for reducing allergy symptoms and a lower likelihood of side effects.

The Icahn School of Medicine at Mount Sinai is an international leader in medical and scientific training, biomedical research, and patient care. It is the medical school for the Mount Sinai Health System, which includes seven hospital campuses, and has more than 5,000 faculty and nearly 2,000 students, residents and fellows. Our unwavering pursuit of intellectual exchange, breakthrough research, and multidisciplinary teamwork propels us ever forward in biomedical discoveries and advances. We pursue ideas that often challenge conventional wisdom to revolutionize the practice of medicine and produce dramatically better outcomes for patients. We make big, bold bets by investing in radical free thinkers and technology at the cutting edge.

ABOUT US: 

Alpha Bronze is a leading provider of investor relations and strategic corporate communications. We have been working with US and non-US private and public companies to build their profiles within the investment community.

Based in New York, Alpha Bronze's single core competency is:

• the development and execution of tailored, strategic investor communication programs.

Our approach is straightforward: by thoroughly and by leveraging our expertise and knowledge of the "Street", we help our clients:

• develop clear and consistent key messages,
• raise their awareness and profiles in the global investment community and,
• ulimately maximize the market value of their stock and company.

OsseoMatrix has developed a direct 3D printing process of biological ceramics which enables the manufacturing of patient specific synthetic bone implants

The bioceramic implants developed by OsseoMatrix fit the anatomical complexity of cranio-maxillo-facial or orthopaedic bone losses, resulting of trauma, infection, tumor.

Market 1: Cranio-facial Market 2: Dental Market 3 Orthopaedic 4 Laboratories

advantage 1 less invasive / advantage 2 same composition as bone / advantage 3 patient specific / advantage 4 regenerative